Formerly angel backed, in 2014, Intica Biomedical was declared bankrupt and closed its door.s INTICA Biomedical, Inc. had offered diagnostic and therapeutic care services for glioblastoma, breast, and pancreatic cancer. The firm had been developing a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supported the company's development program in TNBC INTICA Biomedical's product is a cancer therapeutic; specifically, a companion diagnostic for breast cancer, pancreatic cancer and glioblastoma. These lethal diseases have extremely high mortality rates: the five year survival rate for pancreatic cancer is below three percent, and the survival outlook for a patient diagnosed with glioblastoma lies between 6-12 months. INTICA Biomedicalâs companion diagnostic sought to identify patients which are most likely to respond to INTICAâs novel therapeutics - selectively targetingcancer stem cells, cancer cells and tumor blood vesse
